Moderna

$Moderna(MRNA.US) just dropped about 24% after its closely watched cancer vaccine data appeared to leak early

The Phase 3 melanoma results showed up on the medical news site Oncology Central late this morning and were taken down shortly after, per

Source: StockMarket.News

CRWV rebound, TSM earnings, PPI reaction

October 15, 2026

The tape rotated hard out of the AI complex into the rest of the market. The S&P 500 closed +0.33% at 7,744, the Dow jumped +1.08% to 52,178, the Nasdaq managed only +0.08% to 26,713, and the Russell 2000 rose ~1.3–1.4%. Breadth was solid (roughly 7 of 10 S&P names higher) after an early dip. The 10-year yield fell ~9–10 bp to ~5.08–5.10% even as September PPI printed hot at +1.3% m/m and +6.3% y/y (well above consensus). Stocks absorbed the inflation print via lower yields and a defensive/broad rotation; tech (especially chips and AI infrastructure) lagged after the prior session’s funding scare.

AI Infrastructure Funding Scare Meets Huang’s Pushback

The dominant catalyst remained the re-pricing of AI financing risk, centered on $Coreweave(CRWV.US). Bond yields on its notes spiked toward 15% earlier in the week, CDS widened sharply, and the stock dropped ~15% Wednesday amid Gartner commentary on neocloud longevity and broader worries about leveraged data-center build-outs. Elon Musk’s “yikes” reply to a bond-yield chart added to the noise.

Today $Coreweave(CRWV.US) rebounded ~6% (closing near $69.70) after Nvidia CEO Jensen Huang, speaking in Stockholm, said CoreWeave’s strength is “improving every day,” its cost of capital is decreasing, and he does not see a need for Nvidia to provide a bailout. Nvidia already holds ~10% of the company and has a multi-year capacity purchase commitment. The comments helped stabilize parts of the AI complex (some neocloud and related names pared losses), but credit-market stress had not fully disappeared and the broader semiconductor bid stayed selective. For swing traders, this is a classic sentiment-reset catalyst: the fundamental backlog ($100B+ contracted) and Huang’s endorsement matter more than the overnight bond panic, but elevated funding costs remain a live risk if utilization or pricing disappoints. Watch whether the rebound holds into the next earnings window and whether peers ($Oracle(ORCL.US), $Nebius(NBIS.US), etc.) follow.

$Taiwan Semiconductor(TSM.US) Crushes Numbers, Stock Still Soft

Taiwan Semiconductor reported another record quarter: profit up ~69% y/y, revenue well above guidance, and Q4 revenue outlook of $52.3–54.3B (strong sequential growth). Management reiterated extremely robust demand for leading-edge AI and HPC chips. The U.S.-listed shares still finished lower as the broader AI sell-off overshadowed the beat. The print reinforces the “picks-and-shovels” case for the foundry and its key customers ($NVIDIA(NVDA.US), $AMD(AMD.US), $Broadcom(AVGO.US)), but the market is currently more focused on the financing side of the build-out than on end-demand confirmation. Near-term, the reaction shows how quickly good fundamental news can be discounted when the narrative is about capital intensity and credit.

Other Catalysts and Earnings

$Ericsson(ERIC.US) rose after a solid Q3 beat: organic sales +7%, adjusted EBITA ahead of consensus, Networks strength and cost discipline. Management noted higher component costs will pressure margins next year, but the print was clean enough to drive a clear positive reaction.

Healthcare led sectors (XLV ~+1.8–2%), helped by rotation into defensives and specific catalysts such as $Moderna(MRNA.US) (+4–5% after a Goldman target raise tied to Phase 3 melanoma data optimism). $Eli Lilly(LLY.US), $Unitedhealth(UNH.US) and other large-caps participated.

Analyst activity included upgrades on names such as $Bank of America(BAC.US) (to Outperform) and $Crocs(CROX.US), plus various initiations/resumptions, but nothing that redefined the tape the way the AI credit story and $Taiwan Semiconductor(TSM.US) print did.

Energy lagged (~-1.5%) despite some oil firmness; real estate and rate-sensitive areas benefited from the yield decline.

Healthcare, materials, consumer discretionary and financials led; technology and energy lagged. Equal-weight participation was healthier than the Nasdaq close implies—classic rotation rather than a broad risk-off day.

Notable Movers

Gainers: $Coreweave(CRWV.US) (rebound on Huang), $Ericsson(ERIC.US) (earnings), healthcare names, some Brazil-linked or other idiosyncratic moves from prior sessions continuing in pockets.

Decliners: Select AI/chip and infrastructure names that remained under pressure from the funding narrative; certain industrial or rate-sensitive names that did not fully participate in the Dow strength.

What Matters Next

Whether the $Coreweave(CRWV.US) rebound and Huang’s comments stabilize the AI financing narrative or if bond/CDS stress re-emerges (key for $NVIDIA(NVDA.US) and the broader complex).

More earnings (banks and others still reporting) and whether estimate revisions follow the $Taiwan Semiconductor(TSM.US) beat or stay muted by capital-cost worries.

Bond-market behavior with the 10-year near 5.1% after the hot PPI; a sustained yield drop would support the rotation, while a re-test of recent highs would pressure rate-sensitive and leveraged names.

FinTwit narratives around “AI overbuild vs. real demand” remain live—watch for continued debate on utilization, power, and funding costs versus pure semiconductor strength.

NFA / DYOR. This is market commentary based on public information and is not investment advice.

$Moderna(MRNA.US) is now the best performing stock in the S&P 500 this year, up more than 660% in 2026

That puts a COVID vaccine maker ahead of every AI name in the index, including $Sandisk(SNDK.US) at roughly +566% and $Dell Tech(DELL.US) at roughly +370%. The S&P 500 itself is up about 14%

The run took off on Aug 19, when $Moderna(MRNA.US) and $Merck(MRK.US) said their personalized mRNA cancer vaccine delayed the return or spread of melanoma in a Phase 3 trial. Back in mid-August the stock was still down close to 90% from its pandemic high

Last week added two more catalysts. $Moderna(MRNA.US) rejoined the Nasdaq-100, replacing $Warner Bros. Discovery(WBD.US), and the NYT reported the NIH is planning a public-private push to speed up cancer vaccines. Shares gained 18% on the week and closed at their highest level in more than four years

Full trial data is due Oct 24, and the companies are preparing for regulatory approval next year

The S&P 500's top performer is a science bet, not an AI trade. Most of this move is priced on data nobody outside $Moderna(MRNA.US) and $Merck(MRK.US) has seen yet, so Oct 24 is when the market finds out whether this is a real oncology platform or a stock that ran too far ahead of the evidence

Source: StockMarket.News

Breaking: We found a politician day trading a cancer treatment

Meet Rep. Maria Salazar (R) from Florida

Back on August 19th, Moderna announced their mRNA vaccine successfully prevented melanoma from returning in a Phase 3 trial

The stock had one of the greenest candles you've ever seen and was up ~176% that day alone

Turns out that same day Rep. Salazar bought & sold $Moderna(MRNA.US) within an 8 hour period

It's unclear if she profited or not, but it's safe to assume she bought in early, rode the stock up, and took profits on the way

Not too bad for a sitting politician